DIA 2023: Returning Patient Data
In an interview at the 2023 DIA annual meeting with ACT editor, Andy Studna, Jean Sposaro, program lead, TransCelerate BioPharma, and director, global drug development operations industry collaborations, Bristol Myers Squibb discusses key takeaways from a session she moderated, "Returning Individual Participant Data: A Cultural and Operational Shift Towards Personalized Clinical Trial Options." Sposaro also touches on the concept of "data dumping," which was brought up at the session by David Leventhal, enterprise clinical trial data sharing lead, global data dissemination, Pfizer.
A more in-depth recap of the session itself can be found here.
SCOPE 2024: Todd Everhart of Signant Health Discusses DCTs and Site Burden
February 13th 2024In an interview with ACT editor Andy Studna at SCOPE, Everhart, MD, FACP, clinical vice president, internal medicine, Signant Health discusses decentralized trials and how they may be increasing site burden.
SCOPE 2024: Wendy Morahan of IQVIA Discusses the Use of AI in Clinical Trials
February 13th 2024In an interview with ACT editor Andy Studna at SCOPE, Morahan, senior director, clinical data analytics, IQVIA Technologies discusses how AI can advance trial execution and what stakeholders should be keeping top of mind when choosing technology vendors.
